Maridebart Cafraglutide for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 7 registered trials.

Why this status

  1. 5 Mar 2025: Trial registered, NCT06858839
  2. 12 Mar 2025: Trial started, NCT06858839
  3. 25 Jun 2025: Trial registered, NCT07037433
  4. 25 Jul 2025: Trial started, NCT07037433
  5. 10 Nov 2025: Trial registered, NCT07225686
  6. 19 Dec 2025: Trial started, NCT07225686
  7. 8 May 2026: Trial registered, NCT07575399
  8. 11 May 2026: Trial started, NCT07575399
  9. 6 Jul 2026: Trial registered, NCT07684144
  10. 6 Jul 2026: Trial registered, NCT07684235
  11. 23 Jul 2026: Trial started, NCT07684235
  12. 29 Jul 2026: Trial started, NCT07684144

The trials

NCT06858839: Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

State
Under way
Phase
Phase 3
People
3,853 taking part
Started
12 Mar 2025
Primary completion
21 Jan 2027
Arms
Maridebart Cafraglutide High Dose, Maridebart Cafraglutide Medium Dose, Maridebart Cafraglutide Low Dose
Results
None posted
  1. 5 Mar 2025: Trial registered
  2. 12 Mar 2025: Trial started

NCT07037433: Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

State
Under way
Phase
Phase 3
People
12,800 planned
Started
25 Jul 2025
Primary completion
30 Jun 2028
Arms
Maridebart Cafraglutide
Results
None posted
  1. 25 Jun 2025: Trial registered
  2. 25 Jul 2025: Trial started

NCT07225686: Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

State
Under way
Phase
Phase 3
People
250 planned
Started
19 Dec 2025
Primary completion
20 Aug 2027
Arms
Maridebart Cafraglutide
Results
None posted
  1. 10 Nov 2025: Trial registered
  2. 19 Dec 2025: Trial started

NCT07575399: Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

State
Under way
Phase
Phase 3
People
300 planned
Started
11 May 2026
Primary completion
3 Jan 2028
Arms
MariTide Arm 1, MariTide Arm 2
Results
None posted
  1. 8 May 2026: Trial registered
  2. 11 May 2026: Trial started

NCT07684144: Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

State
Under way
Phase
Phase 3
People
950 planned
Started
29 Jul 2026
Primary completion
26 Dec 2027
Arms
Maridebart Cafraglutide Low Dose Q4W, Maridebart Cafraglutide Medium Dose Q4W, Maridebart Cafraglutide Medium dose Q8W, Maridebart Cafraglutide High Dose Q4W, Maridebart Cafraglutide High Dose Q8W, Maridebart Cafraglutide High Dose Q4W (Received Placebo in the Parent Trial), Maridebart Cafraglutide Low Dose Q4W(Received Very Low Dose Maridebart Cafraglutide in Parent Trial)
Results
None posted
  1. 6 Jul 2026: Trial registered
  2. 29 Jul 2026: Trial started

NCT07684235: Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

State
Under way
Phase
Phase 3
People
3,200 planned
Started
23 Jul 2026
Primary completion
26 Dec 2027
Arms
Maridebart Cafraglutide Low Dose Q4W, Maridebart Cafraglutide Medium Dose Q4W, Maridebart Cafraglutide Medium Dose Q8W, Maridebart Cafraglutide High Dose Q4W, Maridebart Cafraglutide High Dose Q8W, Maridebart Cafraglutide High Dose Q12W, Maridebart Cafraglutide High Dose Q4W (Received Placebo in the Parent Trial), Maridebart Cafraglutide Low Dose Q4W(Received Very Low Dose Maridebart Cafraglutide in Parent Trial)
Results
None posted
  1. 6 Jul 2026: Trial registered
  2. 23 Jul 2026: Trial started

NCT07921316: Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple Doses

State
Not started
Phase
Phase 1
People
356 planned
Started
9 Nov 2026
Primary completion
26 Jul 2027
Arms
Maridebart Cafraglutide: SC Presentation 1, Maridebart Cafraglutide: SC Presentation 2
Results
None posted
  1. 6 Nov 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.